What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.

Jennifer Leeds offers a behind-the-scenes look at the consortia forming to address COVID-19.

Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.

For over 60 years Novartis has been committed to helping people with cardiovascular disease and we remain steadfast in that commitment to this day.

Novartis researchers have discovered a compound that is showing promise against three parasites that cause three neglected diseases.

Florencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.